TSC1 and angiomyolipoma: One study, which discriminated between the two genes, showed no difference between the two groups in the response to everolimus treatment of SEGAs and angiomyolipoma; however, the conclusions were based on only 13 patients with TSC1 variants and 84 patients with TSC2 variants (38).